Cargando…

Early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy

BACKGROUND AND PURPOSE: To evaluate the different response patterns after Stereotactic Body Radiation Therapy (SBRT) and their predictive value in local control and progression of hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Seventy-two HCC patients who were treated with SBRT during 2015–2...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Qi-Qiao, Chen, Yi-Xing, Du, Shi-Suo, Hu, Yong, Yang, Ping, Zeng, Zhao-Chong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014333/
https://www.ncbi.nlm.nih.gov/pubmed/36935858
http://dx.doi.org/10.1016/j.ctro.2022.03.010
_version_ 1784906971276640256
author Wu, Qi-Qiao
Chen, Yi-Xing
Du, Shi-Suo
Hu, Yong
Yang, Ping
Zeng, Zhao-Chong
author_facet Wu, Qi-Qiao
Chen, Yi-Xing
Du, Shi-Suo
Hu, Yong
Yang, Ping
Zeng, Zhao-Chong
author_sort Wu, Qi-Qiao
collection PubMed
description BACKGROUND AND PURPOSE: To evaluate the different response patterns after Stereotactic Body Radiation Therapy (SBRT) and their predictive value in local control and progression of hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Seventy-two HCC patients who were treated with SBRT during 2015–2020 were included in this retrospective study. The assessment was made using MRI, CT, and PET-CT. Local and systemic responses were determined according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria during follow up. Patients were categorized as early responders (complete response during 6 months after radiotherapy) or non-early responders (the rest of the patients). Prognostic factors were determined using multivariate logistic models. RESULTS: The median follow-up was 24.0 months (range, 7.7–74.5 months). We found that 84.7%(61/72) of patients achieved a complete response. Early responses occurred in 45 patients (45/72, 62.5%), and they had 1-, 2-, and 5- year intrahepatic outfield-free survival (OutFFS) rates of 86.2%, 80.3%, and 76.3% vs. 55.3%, 44.7%, and 33.5% in non-early responses patients, whereas the 1-, 2-, and 5- year distant metastasis-free survival (DMFS) were 95.5%, 84.5% and 79.5% and 74.1%, 56.2% and 56.2%, respectively. The 1-, 2-, and 5-year overall survival (OS) were 97.7%, 92.1%, 79.1%, and 85.2%, 53.8%, and 40.3%, respectively. Multivariate analysis revealed that early tumor response was an independent predictor of OutFFS, DMFS, and OS. CONCLUSIONS: Early complete tumor response within 6 months after radiotherapy predicted better intrahepatic outfield-free survival, distant metastasis-free survival, and overall survival outcomes. Confirmation is warranted for early response on SBRT to guide decision making.
format Online
Article
Text
id pubmed-10014333
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-100143332023-03-16 Early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy Wu, Qi-Qiao Chen, Yi-Xing Du, Shi-Suo Hu, Yong Yang, Ping Zeng, Zhao-Chong Clin Transl Radiat Oncol Original Research Article BACKGROUND AND PURPOSE: To evaluate the different response patterns after Stereotactic Body Radiation Therapy (SBRT) and their predictive value in local control and progression of hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Seventy-two HCC patients who were treated with SBRT during 2015–2020 were included in this retrospective study. The assessment was made using MRI, CT, and PET-CT. Local and systemic responses were determined according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria during follow up. Patients were categorized as early responders (complete response during 6 months after radiotherapy) or non-early responders (the rest of the patients). Prognostic factors were determined using multivariate logistic models. RESULTS: The median follow-up was 24.0 months (range, 7.7–74.5 months). We found that 84.7%(61/72) of patients achieved a complete response. Early responses occurred in 45 patients (45/72, 62.5%), and they had 1-, 2-, and 5- year intrahepatic outfield-free survival (OutFFS) rates of 86.2%, 80.3%, and 76.3% vs. 55.3%, 44.7%, and 33.5% in non-early responses patients, whereas the 1-, 2-, and 5- year distant metastasis-free survival (DMFS) were 95.5%, 84.5% and 79.5% and 74.1%, 56.2% and 56.2%, respectively. The 1-, 2-, and 5-year overall survival (OS) were 97.7%, 92.1%, 79.1%, and 85.2%, 53.8%, and 40.3%, respectively. Multivariate analysis revealed that early tumor response was an independent predictor of OutFFS, DMFS, and OS. CONCLUSIONS: Early complete tumor response within 6 months after radiotherapy predicted better intrahepatic outfield-free survival, distant metastasis-free survival, and overall survival outcomes. Confirmation is warranted for early response on SBRT to guide decision making. Elsevier 2022-08-08 /pmc/articles/PMC10014333/ /pubmed/36935858 http://dx.doi.org/10.1016/j.ctro.2022.03.010 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research Article
Wu, Qi-Qiao
Chen, Yi-Xing
Du, Shi-Suo
Hu, Yong
Yang, Ping
Zeng, Zhao-Chong
Early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy
title Early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy
title_full Early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy
title_fullStr Early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy
title_full_unstemmed Early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy
title_short Early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy
title_sort early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014333/
https://www.ncbi.nlm.nih.gov/pubmed/36935858
http://dx.doi.org/10.1016/j.ctro.2022.03.010
work_keys_str_mv AT wuqiqiao earlycompletetumorresponseasasurvivalpredictorinhepatocellularcarcinomapatientsreceivingstereotacticbodyradiationtherapy
AT chenyixing earlycompletetumorresponseasasurvivalpredictorinhepatocellularcarcinomapatientsreceivingstereotacticbodyradiationtherapy
AT dushisuo earlycompletetumorresponseasasurvivalpredictorinhepatocellularcarcinomapatientsreceivingstereotacticbodyradiationtherapy
AT huyong earlycompletetumorresponseasasurvivalpredictorinhepatocellularcarcinomapatientsreceivingstereotacticbodyradiationtherapy
AT yangping earlycompletetumorresponseasasurvivalpredictorinhepatocellularcarcinomapatientsreceivingstereotacticbodyradiationtherapy
AT zengzhaochong earlycompletetumorresponseasasurvivalpredictorinhepatocellularcarcinomapatientsreceivingstereotacticbodyradiationtherapy